DeepMind's Co-Scientist AI helped identify two repurposed medicines that block liver fibrosis in lab tests, including a cancer drug that blocked 91% of a damage response, outperforming human expert selections.
Stanford geneticist uses Co-Scientist to help find new treatments for chronic liver disease and liver fibrosis.
# Uncovering repurposed medicines to fight liver fibrosis
Source: [https://deepmind.google/blog/uncovering-repurposed-medicines-to-fight-liver-fibrosis/](https://deepmind.google/blog/uncovering-repurposed-medicines-to-fight-liver-fibrosis/)
Liver fibrosis is a scarring process that can lead to cirrhosis, which causes more than[1\.4 million deaths each year](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541949/#:~:text=Results,will%20progressively%20decline.)\. Geneticist Gary Peltz at Stanford University School of Medicine is using Co\-Scientist to accelerate the hunt for medicines that can slow, stop, or reverse it\.
In[research published in*Advanced Science*](https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202508751), Peltz’s team explored whether Co\-Scientist could support efforts to identify drugs from the vast literature of existing medicines that could be repurposed to treat fibrosis\. Peltz asked Co\-Scientist to propose three candidates and explain its reasoning\. He also identified two candidate drugs himself, based on their notable presence in the liver fibrosis literature\.
Then Peltz put all five drugs through his lab’s fibrosis testbed, which consists of live human liver cells\. His two drug picks showed no benefit against fibrosis\. By contrast, of the three drug candidates selected by Co\-Scientist, two blocked fibrosis and promoted the regeneration of liver cells\. One of these drugs had only been linked to liver fibrosis in a handful of papers – a needle in the haystack of scientific literature\.
Co\-Scientist’s standout pick was the cancer drug vorinostat\. In Peltz’s experiments, it blocked 91% of a damage response that can drive liver scarring\. Co\-Scientist’s suggestions pointed toward drugs that reshape gene activity, rather than targeting a single fibrosis pathway\. Peltz argues that such drugs deserve serious consideration as treatments for liver fibrosis, and could ultimately help launch a new generation of anti\-fibrotic medicines\.
DeepMind's Co-Scientist AI system helped researchers at the University of Edinburgh generate a novel, experimentally verified hypothesis linking the NLRP3 inflammasome to the mechanism of drug resmetirom in MASH liver disease, potentially enabling targeted combination therapies.
GoogleDeepMind collaborated with global scientific experts to evaluate an AI system that identified new targets for liver fibrosis and fresh approaches to ALS, digesting decades of research.
This Wired article explores how AI could help detect fatty liver disease earlier by analyzing electronic health records and lab reports, potentially enabling prevention and reversal of liver damage.
Two AI-powered science assistants, Google's Co-Scientist and FutureHouse's Robin, can generate hypotheses and analyze biological data for drug retargeting, helping researchers find non-obvious connections across scientific fields.
DeepMind's Co-Scientist AI tool bridges the expertise of two researchers from different biological fields to accelerate ALS research by generating testable hypotheses and identifying RNA-based mechanisms for potential therapies.